~ Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions
~ Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin
~ Recently presented Phase 2 CAD-1005 data demonstrated a >25% absolute reduction in thrombotic events in patients with heparin-induced thrombocytopenia
Source: https://investorshangout.com/post/newpost/92620/